Treatment satisfaction, adherence and behavioral assessment in patients de – escalating from nataliz...
Treatment satisfaction, adherence and behavioral assessment in patients de – escalating from natalizumab to interferon beta
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
De-escalating natalizumab (NTZ) to interferon beta 1b (IFN B 1B) is a possible treatment option in multiple sclerosis (MS) patients interrupting NTZ because of increased risk of progressive multifocal leukoencephalopathy (PML). The aim of this study was to evaluate satisfaction and adherence to treatment, behavioral and fatigue changes in patients...
Alternative Titles
Full title
Treatment satisfaction, adherence and behavioral assessment in patients de – escalating from natalizumab to interferon beta
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3940251
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3940251
Other Identifiers
ISSN
1471-2377
E-ISSN
1471-2377
DOI
10.1186/1471-2377-14-38
